Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 2005, p. 3734-3742, Vol. 49, No. 9
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.9.3734-3742.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Infectious Diseases, Research Institute, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku, Tokyo 162-8655,1 National Hospital Organization, Sendai Medical Center, Miyagino 2-8-8, Miyagino, Sendai 938-8520,2 Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., 3-30-1 Shimura, Itabashi, Tokyo 174-855,3 Department of Microbiology, Kyorin University School of Health Sciences, 476 Miyashita, Hachioji, Tokyo 192-8508,4 National Research Institute for Child Health and Development, Setagaya, Tokyo 157-8535, Japan5
Received 23 February 2005/ Returned for modification 15 April 2005/ Accepted 15 June 2005
|
|
|---|
|
|
|---|
In Japan, the major mechanism of resistance to aminoglycosides is production of aminoglycoside-modifying enzymes (43). The aminoglycoside 6'-N-acetyltransferases [AAC(6')s] are of particular interest because they can modify a number of clinically important aminoglycosides including amikacin, gentamicin, netilmicin, and tobramycin. The AAC(6')-I type confers resistance to amikacin through acetylation of the drug, whereas the AAC(6')-II type acetylates gentamicin. To date, several different genes, designated aac(6')-Ia to aac(6')-Iad, that encode the AAC(6')-I enzymes have been cloned and characterized (42, 50). Genes encoding aminoglycoside-modifying enzymes are often located on integrons (15), sequences that can integrate gene cassettes through site-specific recombination (17), in both plasmid and genomic DNA (15). Class 1 integrons participate in multidrug resistance in P. aeruginosa (27, 28, 37). Class 1 integrons contain two conserved segments (CS) that flank the antibiotic resistance gene cassettes. The 5'-CS contains the intI1 gene, which encodes integrase, the enzyme responsible for catalysis of site-specific recombination (8). The 3'-CS contains the qacE
1 and sul1 genes and an open reading frame (ORF), orf5 (13, 16).
We describe here the genotypic and phenotypic properties of a new multidrug-resistant P. aeruginosa strain that caused a nosocomial outbreak of infection at a hospital in Japan. The isolate carries a class 1 integron that contains an array of three gene cassettes, including one encoding a novel aminoglycoside acetyltransferase.
|
|
|---|
(Takara Bio, Shiga, Japan) and BL21-AI (Invitrogen, Carlsbad, Calif.) were used as hosts for recombinant plasmids and for expression of aac(6')-Iae, respectively. The rifampin-resistant P. aeruginosa mutant ATCC 27853 RFPr was used. P. aeruginosa GN17203 (51) was provided by S. Iyobe (Kitasato University, Sagamihara, Japan). Antibiotics and disinfectants. The antibiotics amikacin, cefoxitin, and imipenem were from Banyu Pharmaceutical Co. (Tokyo, Japan). Arbekacin and dibekacin were from Meiji Seika Kaisha (Tokyo, Japan), aztreonam was from Eizai (Tokyo, Japan), cefotaxime was from Aventis Pharma (Tokyo, Japan), and cefpodoxime and ceftazidime were from Glaxo Smith Kline (Tokyo, Japan). Cefepime was from Bristol Pharmaceuticals (Tokyo, Japan); ciprofloxacin and levofloxacin were from Daiichi Pharmaceutical (Tokyo, Japan); gentamicin, isepamicin, netilmicin, and sisomicin were from Schering-Plough (Osaka, Japan); kanamycin A and B mixture, neomycin B and C mixture, and streptomycin were from Nacalai Tesque (Kyoto, Japan); and meropenem was from Sumitomo Pharmaceutical (Osaka, Japan). Tetracycline was from Lederle Japan Co. (Tokyo, Japan); piperacillin and piperacillin-tazobactam were from Tomiyama Pure Chemical Industries (Tokyo, Japan); moxalactam, tobramycin, and sulfamethoxazole-trimethoprim were from Shionogi and Co. (Osaka, Japan); and kanamycin A, polymyxin B, and silver sulfadiazine were from Sigma Chemical (St. Louis, Mo.). The disinfectants alkyldiaminoethylglycine hydrochloride and povidone iodine were from Yoshida Pharmaceutical Co. (Tokyo, Japan); benzalkonium chloride was from Wako Pure Chemical Industries (Osaka, Japan); and chlorhexidine gluconate was from Ishimaru Pharmaceutical (Osaka, Japan).
In vitro susceptibility to antibiotics and disinfectants. MICs of antibiotics, except polymyxin B and silver sulfadiazine, were determined by the microdilution method. The MICs of polymyxin B and silver sulfadiazine were determined by the agar dilution method according to the protocols recommended by the CLSI (formerly NCCLS), standard M7-A6 (33).
Bactericidal activities of disinfectants were evaluated by time- and dose-dependent killing studies in 96-well microplates. Briefly, 105 microorganisms were incubated at 35°C for 0.5 min to 60 min in 160 µl disinfectants diluted serially twofold. To neutralize the bactericidal activities of the disinfectants, a 10-µl aliquot of each suspension was transferred to 200 µl Trypticase soy broth (Becton Dickinson, Franklin Lakes, NJ) containing 15% Tween 80 (Sigma), 1% soybean lecithin (Nacalai Tesque), and 0.5% sodium thiosulfate (Nacalai Tesque) and then cultured for 24 h. The minimum bactericidal concentrations (MBCs) of disinfectants were recorded relative to the duration of incubation with bacteria.
Transfer of drug resistance among bacteria. Transfer of the drug resistance from P. aeruginosa clinical isolates to a rifampin-resistant mutant of P. aeruginosa, ATCC 27853 RFPr, was examined with the broth mating method (25). After mating, transconjugants were selected on Mueller-Hinton agar plates containing rifampin (200 µg/ml) and imipenem (16 µg/ml) or amikacin (20 µg/ml). Plasmid DNAs from the clinical isolates were purified either with a QIAprep kit (QIAGEN, Tokyo, Japan), by Kado and Lius (24), or method by the method of Domenico et al. (11). With the QIAprep kit or Kado and Liu's method, the bacteria were lysed at different temperatures, 22°C for 5 min or 60°C for 70 min for each method.
PCR of class 1 integrons. To identify the presence of a class 1 integron and to determine the size of any inserted gene cassettes, PCR amplification was performed as described previously (29) with primers 5'-cs and 3'-cs, which are specific for 5'-CS and the 3'-CS of class 1 integrons, respectively, and an Expand High Fidelity PCR system (Roche Diagnostics GmbH, Penzberg, Germany). To determine the content and order of genes in the integron, PCR amplification of the variable region of class 1 integrons was carried out with the primers listed in Table 1. All PCRs were performed with a GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, Foster City, Calif.). Genomic DNAs extracted as described by Sambrook and Russell (41) were used as templates. Amplification conditions were 30 cycles of 94°C for 1 min, 50°C for 1 min, and 72°C for 3 min or 5 min. PCR for amplicons longer than 1 kb was performed with 1.25 U of Z-Taq polymerase (Takara Bio) and 30 cycles of 95°C for 1 s and 68°C for 120 s according to the manufacturer's instructions.
|
View this table: [in a new window] |
TABLE 1. PCR primers
|
DNA sequencing. DNA sequences were determined by the dideoxy chain termination method with an ABI PRISM 3100 sequencer (Applied Biosystems). Homology searches of nucleotide and deduced protein sequences were performed by FASTA and BLAST screens of the DDBJ, GenBank, and EMBL databases. Multiple-sequence alignments and searches for ORFs were performed with GENETYX-WIN software (Genetyx, Tokyo, Japan). The dendrogram for AACs was calculated with the CLUSTAL W Program (49).
Cloning of the aac(6')-Iae gene.
The coding region of aac(6')-Iae (Fig. 1) was amplified by PCR with 2.5 U of Ex Taq DNA polymerase (Takara Bio) and primers aacS1-FC and aacS1-RC (Table 1). The PCR products were cloned into pCRT7/NT (Invitrogen) downstream of the region encoding a six-His tag. Then plasmid pAAC6, which contains aac(6')-Iae, or plasmid pREVAAC6, which contains aac(6')-Iae in the reverse direction, was transformed into E. coli DH5
cells by the CaCl2 method (6). DNA sequences of these cloned fragments were verified by sequencing of both strands as described above.
![]() View larger version (12K): [in a new window] |
FIG. 1. Structure of In2 (GenBank accession no. AF071413) and In113. Gene cassettes are represented as open boxes with an adjacent vertical bar (59-be), shown as heavy solid vertical bars. The novel ORF found in In113 is shown as a hatched box. Genes are indicated by horizontal arrows. IS are represented as gray boxes and are labeled. The sites of the 5'-CS, gene cassettes, 3'-CS, and tni module are indicated just below the construct. IRi and IRt are shown as vertical lines labeled i and t, respectively, and the attI1 sites are shown as open vertical bars toward the left of the constructs.
|
Acetylation of aminoglycosides by recombinant ACC(6')-Iae. Enzymatic acetylation of aminoglycosides was done as described previously (53). Recombinant AAC(6') from actinomycete strain #8 was provided by J. Ishikawa (National Institute of Infectious Diseases, Tokyo, Japan). Various aminoglycosides were incubated with recombinant AAC(6')-Iae or AAC(6') as a positive control in the presence of acetyl coenzyme A, and the acetylated derivatives were detected by thin-layer chromatography. The reaction was carried out at 37°C for 30 min to 12 h.
Pulsed-field gel electrophoresis (PFGE). Genomic DNA from P. aeruginosa was prepared by the procedure of Grundmann et al. (14) and digested overnight with 10 U of SpeI, XbaI, or HpaI (Takara Bio). The DNA fragments were separated on 1.0% agarose gels in 0.5x Tris-borate-EDTA buffer with a CHEF Mapper system (Bio-Rad Laboratories, Hercules, Calif.) at 6 V/cm for 20 h.
Southern hybridization. We performed Southern blotting to identify the location of In113. A 465-bp segment of aac(6')-Iae and a 362-bp segment of blaIMP-1 amplified by PCR were labeled with horseradish peroxidase and used as probes.
Nucleotide sequence accession number. The nucleotide sequence of In113 reported here has been deposited in the EMBL/GenBank/DDBJ databases and assigned accession number AB104852.
|
|
|---|
![]() View larger version (35K): [in a new window] |
FIG. 2. (A) PFGE of SpeI-, XbaI-, and HpaI-digested genomic DNA from multidrug-resistant P. aeruginosa IMCJ2.S1. (B) Southern blotting of the same gels with an aac(6')-Iae probe. Lanes M, HindIII-digested phage DNA as a size marker.
|
|
View this table: [in a new window] |
TABLE 2. In vitro susceptibilities of P. aeruginosa IMCJ2.S1 and P. aeruginosa ATCC 27853 to various antimicrobial agents
|
Detection of an integron in P. aeruginosa IMCJ2.S1. To determine if strain IMCJ2.S1 carried a class 1 integron, PCR analysis specific for class 1 integrons was performed (29). Strain IMCJ2.S1 yielded a 2.5-kbp PCR product, whereas E. coli CSH2 harboring plasmid NR1 (32), which carries In2 (30), yielded a 1.0-kbp PCR product. P. aeruginosa ATCC 27853 did not yield PCR products. These results suggest that strain IMCJ2.S1 and E. coli CSH2 each carry a class 1 integron and that this integron contains additional sequences that are not present in In2.
The class 1 integron frequently contains the tniB and tniA genes downstream of the 3'-CS (13, 16). To confirm the presence of a class 1 integron in IMCJ2.S1 and to elucidate the structure downstream of the 3'-CS, we performed PCR specific for intI1, qacE
1, sul1, and their spanning or marginal regions. PCRs yielded the expected products (Table 1), with the exception of a 4.7-kbp fragment after amplification with int-R and sul-R and a 2.5-kbp fragment after amplification with tniB-F and tniA-R. These data show that IMCJ2.S1 carries a class 1 integron and that this integron contains intI1-sul1 in a 4.7-kbp region, sul1-tniB in a 6.5-kbp region, and tniB-tniA in a 2.5-kbp region (Fig. 1).
Identical results were obtained for the other six isolates from the outbreak.
Structure of the class 1 integron found in P. aeruginosa IMCJ2.S1. We analyzed the sequences of the PCR products to determine the structure of the class 1 integron of IMCJ2.S1. The 5'-CS contained intI1, the attI1 recombination site with a 7-bp core site sequence of GTTAGAA (45), and the TGGACA (35) and TAAACT (10) hexamers separated by 17 bp, which is characteristic of the Pc promoter (7, 45). Although TTGTTA (35) and TACAGT (10) hexamers separated by 14 bp were present again downstream of the Pc promoter, this region is not likely to act as the P2 promoter, because there is no GGG sequence (7, 45).
Between the 5'-CS and 3'-CS, there were three gene cassettes (Fig. 1). The 880-nucleotide (nt) cassette contained the metallo-ß-lactamase gene blaIMP-1 (35) and a 127-nt 59-base element (59-be) site, a site for site-specific cointegration events (Fig. 3), and this cassette was identical to one described previously (2, 35). The 647-nt cassette contained an ORF and a 68-nt 59-be site (Fig. 3). The sequence of this 647-nt cassette was not found in any database, and therefore, we named this integron In113 (Fig. 1). The ORF in the 647-nt cassette encoded a 183-amino-acid (aa) product that was 55.2% identical to a 6'-N-aminoglycoside acetyltransferase, AAC(6')-Ia (48), and 57.1% identical to AAC(6')-Iq of Klebsiella pneumoniae (4). We named the predicted protein AAC(6')-Iae according to the standard nomenclature (42).
![]() View larger version (16K): [in a new window] |
FIG. 3. Structures of 59-be of In113. Seven-base-pair putative core sites in the left-hand (LH) and right-hand (RH) consensus sequences were designated 1L and 2L and 2R and 1R, respectively. The putative recombination event occurs between the G and the first T in the 1R core site and is indicated by vertical arrows (see reference 45). The relative orientations of 1L, 2L, 2R, and 1R are indicated by arrows under the sequence. An extra base in 2L is marked with an asterisk. Inverted repeats are underscored with arrows.
|
![]() View larger version (24K): [in a new window] |
FIG. 4. Dendrogram of aminoglycoside 6'-N-acetyltransferases for comparison with AAC(6')-Iae. The dendrogram was calculated with the CLUSTAL W program. Branch lengths correspond to the number of amino acid exchanges for AAC proteins. EMBL/GenBank/DDBJ accession numbers of AAC proteins are as follows: AAC(6')-Ia, M18967-1; AAC(6')-Ib, M23634; AAC(6')-Ic, M94066; AAC(6')-Id, X12618; AAC(6')-Ie, M13771; AAC(6')-If, X55353; AAC(6')-Ig, L09246; AAC(6')-Ih, L29044; AAC(6')-Ii, L12710-1; AAC(6')-Ij, L29045; AAC(6')-Ik, L29510; AAC(6')-Il, Z54241 and U13880; AAC(6')-Im, Z54241-2; AAC(6')-Iq, AF047556-1; AAC(6')-Ir, AF031326; AAC(6')-Is, AF031327; AAC(6')-It, AF031328; AAC(6')-Iu, AF031329; AAC(6')-Iv, AF031330; AAC(6')-Iw, AF031331; AAC(6')-Ix, AF031332; AAC(6')-Iy, AF144880; AAC(6')-Iz, AF140221; AAC(6')-Iaa, NC_003197; AAC(6')-Iad, AB119105; AAC(6')-IIa, M29695; AAC(6')-IIb, L06163; AAC(6')-29a, AF263519; AAC(6')-29b, AF263519.
|
![]() View larger version (63K): [in a new window] |
FIG. 5. Alignment of the AAC(6')-Iae amino acid sequence with those of four members of the AAC(6')-I subfamily. Identical residues are marked with black boxes. Four motifs, including the highly conserved motif B, are underlined. A conserved region of 21 amino acids, described by Shmara et al. (44), is indicated by a dotted line. GenBank accession numbers are given in brackets to the right of AAC names. C. diversus, Citrobacter diversus; C. freundii, Citrobacter freundii.
|
1 (39), sul (47), and orf5 (30, 37). There were three inserted sequences (IS), IS1326 (3), IS1353 (3), and IS26 (38), in the region downstream of the 3'-CS (Fig. 1). IS26 is known to be inserted into the tniA coding region of the tni transposition module (30).
Drug resistance mediated by the AAC(6')-Iae enzyme.
To examine the role of AAC(6')-Iae in aminoglycoside resistance, a recombinant plasmid, pAAC6, carrying aac(6')-Iae from strain IMCJ2.S1 was transformed into E. coli DH5
. E. coli harboring pAAC6 showed significantly lower susceptibility to amikacin, dibekacin, isepamicin, kanamycin, netilmicin, sisomicin, and tobramycin than the parent strain and the negative control. MICs for other aminoglycosides, including arbekacin, gentamicin, and streptomycin, were unchanged (Table 3). These results indicate that aac(6')-Iae is involved in aminoglycoside resistance.
|
View this table: [in a new window] |
TABLE 3. Aminoglycoside resistance patterns of E. coli DH5 alone or harboring plasmids with or without aac(6')-Iae
|
![]() View larger version (40K): [in a new window] |
FIG. 6. Thin-layer chromatogram of aminoglycosides incubated with AAC(6')-Iae protein (I) or with AAC(6') from Streptomyces lividans TK21 as a control (II) (53) in the presence (+) or absence () of acetyl coenzyme A. KAN, kanamycin; AMK, amikacin; TOB, tobramycin; ABK, arbekacin; GEN, gentamicin; NEO, neomycin; DIB, dibekacin; NET, netilmicin; SIS, sisomicin; ISE, isepamicin.
|
The extracts from the seven clinical isolates and P. aeruginosa GN17203 were separated by agarose gel electrophoresis, and Southern blotting with aac(6')-Iae or blaIMP-1 as a probe was performed. A plasmid that contained blaIMP-1 but not aac(6')-Iae was detected in P. aeruginosa GN17203. Despite repeated attempts (three times per procedure), we did not detect this plasmid by ethidium bromide staining or Southern blotting in any of the clinical isolates (data not shown). In contrast, Southern hybridization of SpeI-, XbaI-, and HpaI-digested genomic DNAs of the seven clinical isolates revealed 50-kb, 250-kb, and 60-kb aac(6')-Iae-positive fragments, respectively (Fig. 2). These fragments were also positive for blaIMP-1 (data not shown). To examine whether the drug-resistant phenotype of P. aeruginosa IMCJ2.S1 can be transferred by conjugation, IMCJ2.S1 was incubated with P. aeruginosa ATCC 27853 RFPr. Carbapenem resistance was transferred from P. aeruginosa GN17203 to P. aeruginosa ATCC 27853 RFPr, consistent with the results reported by Watanabe et al. (51). In contrast, resistance to amikacin or carbapenem was not transferred from IMCJ2.S1 to ATCC 27853 RFPr. These results suggest that In113 is located in the chromosome, and not on a plasmid, of P. aeruginosa IMCJ2.S1.
Resistance of IMCJ2.S1 to fluoroquinolones. IMCJ2.S1 was highly resistant to fluoroquinolones (Table 2). This resistance is typically associated with mutations in the QRDR within gyrA, gyrB, parC, and parE, which encode DNA gyrase or topoisomerase IV in P. aeruginosa (1, 21, 26, 31). Therefore, we screened IMCJ2.S1 mutations within the QRDR. Compared to the gyrA sequence of strain PAO1 (46), the gyrA sequence of IMCJ2.S1 contained an ACC-to-ATC mutation in codon 83 that causes a Thr-to-Ile change in the A subunit of DNA gyrase. IMCJ2.S1 also had a TCG-to-TTG mutation in codon 87 of parC that causes a Ser-to-Leu substitution in the C subunit of topoisomerase IV. IMCJ2.S1 had four mutations in gyrB: CGC to CGT in codon 396, AAA to AAG in codon 408, GAA to GAG in codon 484, and TTG to CTG in codon 513. There were four mutations in parE: GAA to GAG in codon 448, GGT to GGC in codon 472, AGT to AGC in codon 474, and GCC to GCT in codon 477. These mutations in gyrB and parE did not lead to amino acid changes in the proteins encoded (1, 31). Identical results were obtained with the other six clinical isolates. Together, these results indicate that IMCJ2.S1 contains mutations in gyrA and parC that are associated with its fluoroquinolone resistance.
|
|
|---|
AAC(6')-Iae from P. aeruginosa strain IMCJ2.S1, which was responsible for an outbreak of catheter-associated urinary tract infections, acetylated all of the aminoglycosides with 6'-NH2, and acetylation of arbekacin and neomycin appeared to be complete (Fig. 6I). However, E. coli DH5
(pAAC6), expressing exogenous AAC(6')-Iae, was sensitive to arbekacin and did not show reduced susceptibility to neomycin. Arbekacin and neomycin were shown to retain their antibiotic effects even after they were acetylated by AAC(6') from an arbekacin-resistant actinomycete strain at the 6' positions (53). Enterococcus faecium producing AAC(6')-Ii was susceptible to neomycin even though AAC(6')-Ii acetylated neomycin (52). These results suggest that acetylation of arbekacin and neomycin at 6' positions does not affect the antimicrobial activities of these drugs. We cannot exclude the possibility that the antimicrobial activity observed after treatment with AAC(6')-Iae is due to residual arbekacin or neomycin that was not acetylated.
E. coli DH5
expressing AAC(6')-Iae was sensitive to gentamicin (Table 3), although AAC(6')-Iae showed only partial acetylation of gentamicin (Fig. 6I). The sensitivity of these bacteria to gentamicin appears to be due to incomplete acetylation of gentamicin, which was observed with AAC(6') from an arbekacin-resistant actinomycete strain (53)(Fig.6II). Commercially available gentamicin is a mixture of a number of derivatives of gentamicin, such as gentamicin C1, C1a, C2, and C2b, that have modifications of position 6'. Gentamicin C1 and C2b carry a methyl group on N-6' and are refractory to AAC(6')-I enzymes (42, 50). We cannot exclude the possibility that acetylated gentamicin components, which are more susceptible to AAC(6')-I enzymes, retain antibiotic activity.
In the present study, we identified In113, a class 1 integron that contains a novel aminoglycoside resistance gene, aac(6')-Iae. Several classes of integrons have been categorized on the basis of the structure of integrase (15, 40). The most common integrons in P. aeruginosa are those of class 1 (27, 28, 37). Because their structures are very similar to each other, the direct origin of In113 could be from In2 (30), which was originally isolated from Shigella flexneri in Japan in the late 1950s (32) (Fig. 1).
IMCJ2.S1 was resistant to all antibiotics tested except arbekacin and polymyxin B (Table 2). However, the presence of In113 and the mutations in gyrA and parC of the QRDR are not sufficient to explain the multidrug resistance of this strain. Alterations of gyrA and parC are known to contribute to fluoroquinolone resistance (1, 21, 26, 31). The blaIMP-1 gene cassette, which encodes the IMP-1 metallo-ß-lactamase, confers resistance to all ß-lactams except monobactams (2, 27, 35). The aac(6')-Iae gene cassette, which encodes AAC(6')-Iae, confers resistance to amikacin, dibekacin, isepamicin, kanamycin, netilmicin, sisomicin, and tobramycin (Table 3). The variant aadA1 gene cassette, which encodes aminoglycoside 3"-adenylyltransferase, confers resistance to streptomycin (18, 22). The sul1 gene, which encodes dihydropteroate synthetase type I, confers resistance to sulfamethoxazole (47). Thus, the resistance of IMCJ2.S1 to aztreonam, gentamicin, tetracycline, trimethoprim, and silver sulfadiazine appears to be related to another, unidentified resistance factor(s).
In conclusion, we describe here a novel aminoglycoside 6'-N-acetyltransferase gene contained on a class 1 integron in a P. aeruginosa strain that caused a nosocomial outbreak of urinary tract infections. In113 may spread across Japan, because ß-lactams, including carbapenems and aminoglycosides, are frequently used as therapeutic agents against P. aeruginosa and methicillin-resistant Staphylococcus aureus (20, 23). Surveillance for multidrug-resistant P. aeruginosa containing In113 is under way at several medical care facilities in the Sendai area of Japan.
This study was supported by Health Sciences Research grants from the Ministry of Health, Labor, and Welfare of Japan (H15-SHINKO-11 and H16-TOKUBETSU-027).
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»